About us

GLP Atlas is an independent reference on GLP-1, incretin and insulin medicines for readers in the United States and Canada. We explain what each medicine is approved for, how it is dosed according to its official label, its risks, and the legal ways to obtain it.

We do not sell, ship or broker medicines. We never process orders and never ask readers to contact us to buy anything.

Who writes and reviews the content

• Editor: Dr. George Grunberger — responsible for every page and every update.
• Medical review: pending — clinician review in progress.
• Last site-wide review: October 20, 2026.

What we cover

• 26 GLP-1, incretin, insulin and emergency diabetes medicines, plus two pipeline drugs.
• Side-by-side comparisons, buying guides for the US and Canada, and short answers to common questions.
• Prices, approvals and generics that change often — each page shows the date it was last checked.

How we work

Facts come from primary sources: FDA and Health Canada labels, manufacturer releases and peer-reviewed trials. We do not publish anonymous claims or user testimonials. Read the full editorial policy.

Contact

Corrections and editorial questions: contact@glpatlas.com. General enquiries: glp1atlas@gmail.com.